About this trial
This is a phase Ib study of the safety and performance of a novel intravesical contrast-enhanced Magnetic Resonance Imaging protocol for determination of bladder cancer stage prior to transurethral resection of bladder tumor (21 subjects) or prior to radical cystectomy for muscle invasive disease (21 subjects). Subjects will undergo a single MRI study: a pre-contrast, single breath hold image followed by sterile placement of a temporary urethral catheter for instillation of a 50mL solution containing Gadobutrol (4 mM) plus ferumoxytol (5 mM) and then a second, post-contrast image. Images will be reviewed by two dedicated abdominal radiologists, who are blinded to the pathologic staging, for determination of tumor presence and depth of bladder wall penetration.
Eligibility criteria
Qualifiers
18 to 90 years of age
Able to understand and willing to sign a written informed consent document
A papillary tumor identified by cystoscopy that has been scheduled for TURBT OR histologically proven MIBC that is clinically localized and amenable to surgical resection with curative intent.
Performance status of ECOG 0 or 1
Disqualifiers
Severe hypersensitivity reaction to gadobutrol or ferumoxytol.
Severe claustrophobia that will prevent completion of the MRI study.
Any MRI-non-compatible implanted device, prosthetic or pacemaker.
Known or suspected metastatic disease.
Trial design
Treatments tested in this trial
- Magnetic Resonance Imaging
- Gadobutrol intravesical administration (4mM)
- Ferumoxytol intravesical administration (5 mM)
Treatment groups
Sponsors and collaborators
Jodi Maranchie
Lead sponsor
University of Pittsburgh
Sponsor institution
National Cancer Institute (NCI)
Collaborator